source
- White House reviews FDA's new prescription drug user fee agreement for 2028-2032The White House is currently reviewing a recently negotiated agreement between the FDA and the biopharma industry that determines the level of prescription-drug user fees for the period 2028 throug…
- Eli Lilly stops disclosing Phase 1 pipeline, making early-stage projects invisible in earnings decksEli Lilly has become more opaque as its size grows, choosing to stop public disclosure of its early-stage research efforts. The shift was noted earlier this year when the company removed Phase 1 pr…